Nov 08, 2019 Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 07, 2019 Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
Sep 30, 2019 Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019
Sep 26, 2019 Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Sep 16, 2019 Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
Aug 08, 2019 Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
May 09, 2019 Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
May 01, 2019 Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab